

Gender differences in patients with PsA in a German disease register

Lisa Lindner¹, Anja Weiß¹, Andreas Reich¹, Anja Strangfeld¹, Anne C. Regierer¹

¹ German Rheumatism Research Centre Berlin (DRFZ), Epidemiology and Health Services Research, Berlin



Lancet Summit 2022 P.48

Background

Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the musculoskeletal system, skin, and nails. Although some gender related differences in clinical manifestations and treatment efficacy have been described before, these differences are not well enough elucidated.

Objective




- Describe gender differences for patients with PsA in
 - clinical manifestations
 - patient-reported outcomes (PRO)

Method

Data Source


- German disease register RABBIT-SpA
- Observational cohort
- Baseline data between 2017 and 2022
- N=1458 (patients with PsA), 861 women | 597 men



Results

	861	N	597
Baseline characteristics			
	53 (12.3)	Age, mean (SD)	51 (12.4)
	29.1 (6.5)	BMI, mean (SD)	29.0 (5.1)
	6.4 (7.4)	Duration since joint diagnosis (yrs.) , mean (SD)	5.8 (7.0)
	290 (34)	≥ 3 comorbidities, n (%)	158 (27)
Outcome parameter			
	27.2 (13.6)	DAPSA*, mean (SD)	24.9 (13.6)
	309 (36)	CRP > 5mg/l*, n (%)	229 (38)
	7.2 (14.3)	BSA*, mean (SD)	10.3 (15.7)
	298 (35)	Nail psoriasis*, n (%)	283 (48)
	158 (19)	Dactylitis*, n (%)	125 (21)
	8.4 (8.3)	TJC (1-68)*, mean (SD)	7.4 (7.5)
	4.9 (4.9)	SJC (1-66), mean (SD)	4.9 (4.9)
	3.4 (2.7)	Enthesitis counts (1-16)*, n (%)	2.6 (2.0)
	4.5 (2.2)	PSAID (0-10)*, mean (SD)	3.8 (2.2)
	6.0 (6.6)	DLQI, mean (SD)	5.5 (5.8)
	1.1 (0.6)	HAQ*, mean (SD)	0.7 (0.6)

*Significant differences (p<0.05) of group comparison between men and women



Conclusion

- Clinical parameter differ between female and male PsA patients
- Skin related symptoms were more severe in men
- Women had worse enthesitis, TJC, and physician measured joint disease activity
- Most patient-reported parameter were worse in women

For a personalized management of PsA patients, these gender differences should be taken into account.

Funding: RABBIT-SpA is jointly supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viartis. RABBIT-SpA is independent in the conduct of the study, analyses, and publication of results. We thank all participating patients and their physicians.